Aster Officially Launches VIP and Market Maker Tiered Fee System, Users Enjoy Up to 0bps Maker Fee
According to official news, the decentralized trading platform Aster has announced the launch of a tiered fee rate plan for VIP users and market makers, with dynamic adjustment of fee rates based on a 14-day rolling trading volume.
As disclosed in the official fee schedule, there are six tiers from VIP1 to VIP6, with trading volume thresholds ranging from $5 million to $1 billion. The highest level, VIP6 (14-day trading volume ≥ $1 billion), can enjoy a 2.5bps taker fee rate and a 0bps maker fee rate, which is over 28% lower than the base rate. The fee rates are automatically updated daily at the end of UTC time based on trading volume.
The MM1-MM3 tiering standard is based on a combination of trading volume ($100 million to $1 billion) or the proportion of maker volume (0.5%-4%), with rebate strength increasing with the level. MM3 level market makers can receive a 2.5bps base rate plus a 1bps rebate, resulting in an actual maker fee rate of -1bps.
Additionally, the plan simultaneously implements a referral reward mechanism, where the referrer's earnings are directly linked to the net fee contribution of the referred user.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Crypto prices
More
